Research · Sep 3, 2026
[HCA] HCA Healthcare Thesis 2026: Commercial Mix Advantage Drives Through Hospital Cycle
HCA Healthcare Inc. FY2025 revenue ~$71-73B (+5-7%) with adj. EPS ~$24-25 reflecting continued patient volume recovery + selected commercial payer mix advantage + selected pricing + selected operational discipline + selected acquisition integration partially offset by selected labor cost inflation + selected Medicare/Medicaid reimbursement dynamics. Largest US for-profit hospital operator. Founded 1968 by Drs. Thomas Frist Sr. + Thomas Frist Jr. + Jack Massey in Nashville Tennessee (selected as Hospital Corporation of America). Headquartered in Nashville Tennessee. ~190 hospitals + ~125 freestanding surgery centers + ~2,000+ care sites (urgent care + freestanding emergency rooms + physician practices) across 20 US states + UK. Service mix: Inpatient Services ~64% ($45-48B) + Outpatient Services ~32% ($22-25B; selected outpatient growth strategy shifting toward lower-cost outpatient settings) + Other 4%. Payer mix: Commercial 60% (selected higher than peers ~50-55% — selected geographic + demographic concentration in suburban/exurban markets with selected commercial insurance penetration; commercial rates ~3-5x Medicare rates) + Medicare 25% + Medicaid 15%. Geographic concentration: Texas 25% + Florida 20% + Tennessee/Virginia 15% + Colorado/mountain 10% + selected. CEO Sam Hazen since January 1, 2019 (succeeded Milton Johnson CEO 2014-2018 who became Executive Chair; Hazen ex-HCA COO 2016-2019 + Group President; ~30+ year HCA career). Hazen tenure executed continued operational excellence + selected commercial mix optimization + selected acquisitions + selected labor cost management + aggressive capital return ($5-7B annual buybacks). Capital return: dividend $2.40-2.52/share + buybacks $5-7B (~3-5%/yr share count reduction; share count 290M FY2022 → 250M FY2025E ~14% reduction over 3 years); net debt $40-42B (high leverage); Baa2/BBB- investment grade. FY2026 thesis: commercial mix + operational excellence + capital return. Risks: Medicare/Medicaid reimbursement, labor costs, regulatory environment.